Skip to main content
SpringerLink
Log in

ICER reports on spinal muscular atrophy and CVD therapies

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Comparative Effectiveness Public Advisory Council

References

  1. ICER. ICER's Assessment Finds Spinraza and Zolgensma Provide Substantial Health Benefits for People with Spinal Muscular Atrophy. Internet Document : 22 Feb 2019. Available from: URL: https://icer-review.org/announcements/sma_evidence_report/

  2. ICER. ICER to Publish Upcoming Assessment on Additive Cardiovascular Disease Therapies. Internet Document : 22 Feb 2019. Available from: URL: https://icer-review.org/announcements/additive-cvd-topic/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER reports on spinal muscular atrophy and CVD therapies. PharmacoEcon Outcomes News 823, 1 (2019). https://doi.org/10.1007/s40274-019-5691-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5691-2

Search

Navigation